HEPTA Medical Secures €5.7 Million Series A, Led by BPI France to Advance Minimally Invasive Lung Cancer Treatment
September 04 2024 - 3:06AM
Business Wire
- Founded in 2019 by Sofinnova’s medtech acceleration team, MD
Start
- The funds will be used for the 510(k) regulatory approval
process for the first version of HEPTA Medical’s microwave ablation
platform and to initiate its clinical trials
HEPTA Medical (“HEPTA”), a private medical device company
dedicated to providing an efficient, safe, and minimally-invasive
thermal ablation therapy for early-stage lung cancer, today
announced it has successfully raised €5.7M in the first close of
its Series A funding round. The investment was led by BPI France
with the participation of M&L Healthcare and Clery IG.
This financing round will enable HEPTA to initiate the US
regulatory approval process for the first version of its microwave
ablation platform and to commence its clinical trials. Lung cancer
is the leading cause of cancer-related deaths worldwide. As lung
cancer screening programs are being implemented, the management of
early-stage lung cancer patients has become an increasingly urgent
concern for healthcare organizations. HEPTA aims to address this
need by offering a controlled, incision-less technology, that
provides a minimally invasive approach to treat patients quickly,
safely, and efficiently.
“We are grateful for our new investors, and excited to bring
microwave ablation therapy to new heights. In August, we obtained
our first proprietary patent, completing our three patent families
under license. We have multiple upcoming milestones, including the
release of early preclinical trial results conducted in
collaboration with world-renowned centers, which we’ll publish at
the CIRSE conference in September,” says Dr. Thomas Bancel, CEO of
HEPTA Medical.
The chairman of the board of directors, Gérard Hascoët, a
Sofinnova Venture Partner, will be joined by Philippe Boucheron and
Jocelyn Kum as representatives for BPI France and M&L
Healthcare, respectively.
“We are thrilled to be part of HEPTA Medical’s journey as they
push the boundaries of innovation in minimally invasive lung cancer
treatment. This investment aligns with our commitment to support
groundbreaking medical technologies that have the potential to
significantly improve patient outcomes. HEPTA’s unique approach to
thermal ablation therapy, combined with their dedicated team and
cutting-edge technology, positions them at the forefront of
transforming lung cancer care. We are confident that HEPTA Medical
will achieve significant milestones in the near future and are
excited to support their continued growth and success,” comments
Philippe Boucheron, Deputy Chief of Life Sciences Investments at
BPI France.
HEPTA Medical was founded in 2019 by Sofinnova medtech
acceleration team, MD Start. HEPTA develops a flexible microwave
ablation probe compatible with any lung navigation system. It is
equipped with a proprietary patented tissue temperature sensor that
enables monitoring of the growth of the ablation zone in-situ and
in real-time during endobronchial ablation procedures. The device
also incorporates predictive software, powered by artificial
intelligence, which combines procedural CT images and temperature
measurements to display the ablation zone in real-time to the
clinician during the procedure.
About HEPTA Medical:
HEPTA Medical develops a flexible microwave ablation platform
for the minimally-invasive treatment of early-stage lung cancer
patients. Its incision-less technology can deliver thermal energy
through the airway. HEPTA Medical’s microwave ablation probe is
equipped with a proprietary patented temperature sensor enabling to
monitor and control the growth of the ablation zone during the
procedure. HEPTA Medical was founded in 2019 out of MD Start – the
medical device incubator based in France and backed by Sofinnova
Partners. The company is based in Suresnes, France.
For more information, please visit:
https://www.heptamed.com/
About BPI France:
Bpifrance Investissement is the management company that handles
Bpifrance's equity investments. Bpifrance is the French national
investment bank: it finances businesses – at every stage of their
development – through loans, guarantees, equity investments and
export insurances. Bpifrance also provides extra financial services
(training, consultancy) to help entrepreneurs meet their challenges
from innovation to export.
For more information, please visit:
https://www.bpifrance.com/
About M&L Healthcare:
M&L Healthcare is a Singapore based family office focused on
long-term investments in the healthcare sector. With a strategic
emphasis on life sciences, medical technologies, and healthcare
services, the firm partners with companies across all stages to
drive innovation, growth, and improved patient outcomes
globally.
For more information, please visit:
https://www.mnlhealthcare.com/
About Clery IG:
Clery IG is a French based family office specializing in
strategic investments across diverse sectors, with a focus on
healthcare, technology, and real estate. Leveraging deep industry
expertise and a global network, Clery IG partners with companies to
drive sustainable growth, innovation, and long-term value
creation.
For more information, please visit:
http://clery-ig.fr/#contact
About Sofinnova Partners:
Sofinnova Partners is a leading European venture capital firm in
life sciences, specializing in healthcare and sustainability. Based
in Paris, London and Milan, the firm brings together a team of
professionals from all over the world with strong scientific,
medical and business expertise. Sofinnova Partners is a hands-on
company builder across the entire value chain of life sciences
investments, from seed to later-stage. The firm actively partners
with ambitious entrepreneurs as a lead or cornerstone investor to
develop transformative innovations that have the potential to
positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established
venture capital firm in Europe, with 50 years of experience backing
over 500 companies and creating market leaders around the globe.
Today, Sofinnova Partners has over €2.8 billion under management.
For more information, please visit: www.sofinnovapartners.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240903236936/en/
Dr. Thomas BANCEL, CEO: thomas@heptamed.com